13-Oxyingenol-13-dodecanoate

13-Oxyingenol-dodecanoate (13OD) is a tumor suppressor agent. 13-Oxyingenol-dodecanoate has anti-HIV-1 activity with EC₅₀ value of 33.7 nM^[1].13-Oxyingenol-dodecanoate can induce the expression of ULK1 to effect mitochondrial dysfunction and cellular autophagy. 13-Oxyingenol-dodecanoate also increases the expression of BAX and suppresses the expression of BCL-2 to effect apoptosis^[2]. In Vitro:13-Oxyingenol-dodecanoate (0, 3.125, 6.25, 12.5, 25 and 50 µM, 72 h) significantly reduces A549, H460, and BEAS-2B cells cell proliferation^[2].
13-Oxyingenol-dodecanoate (0, 5, 10 and 20 µM, 72 h) can inhibit the antiapoptotic protein BCL-2 and increasing the pro-apoptotic protein BAX in NSCLC cells^[2].
13-Oxyingenol-dodecanoate (0, 5, 10 and 20 µM, 72 h) influences the effect on the intracellular redox state redox state, 13-Oxyingenol-dodecanoate leads to a loss of mitochondrial membrane potential, 13-Oxyingenol-dodecanoate causes concentration-dependent mitochondrial dysfunction in A549 and H460 cells^[2].
13-Oxyingenol-dodecanoate (0, 5, 10 and 20 µM, 72 h) induces significant up-regulation of ATG5, degradation of p62, and dose-dependent conversion of LC3 I to LC3 II. 13-Oxyingenol-dodecanoate induces concentration-dependent autophagy in A549 and H460 cells^[2].
13-Oxyingenol-dodecanoate (0, 5, 10 and 20µ M, 72 h) significantly increased the expression of ULK1 in NSCLC cells^[2].
In Vivo:13-Oxyingenol-dodecanoate (2.5 mg/kg and 5 mg/kg; ip; every two days for two weeks) significantly inhibites the growth of transplanted tumors in a xenograft model by injecting H460 cells subcutaneously into nude mice^[2].